Glenn DA, Pate V, Zee J, Walter EB, Denburg MR, Hogan S, Falk RJ, Mottl A, Layton JB. Influenza vaccine administration and effectiveness among children and adults with glomerular disease. Kidney Int Rep. 2024 Feb 9;9(2):257-65. doi: 10.1016/j.ekir.2023.10.031
Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments. Respirology. 2015 Nov 6;20(8):1172-81. doi: 10.1111/resp.12656
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30;2(4):e000208. doi: 10.1161/JAHA.113.000208.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x